IQVIA, Flagship Pioneering Partner on Biopharma Innovation Acceleration

IQVIA and Flagship Pioneering announce a strategic collaboration to accelerate the development of breakthrough life sciences companies. The collaboration will provide Flagship's ecosystem of biopharma companies with access to IQVIA's comprehensive capabilities, including information assets, analytics, and domain expertise across the drug development life cycle. IQVIA's cutting-edge technologies in AI, analytics, and clinical trial design will be utilized to create a more efficient and effective approach to drug development and early commercial viability.

IQVIA (NYSE: IQV) and Flagship Pioneering have announced a strategic collaboration aimed at accelerating the development of breakthrough life sciences companies. The partnership will provide Flagship's ecosystem of biopharma companies with access to IQVIA's comprehensive capabilities, including information assets, analytics, and domain expertise across the drug development life cycle.

The collaboration will leverage IQVIA's cutting-edge technologies in artificial intelligence (AI), analytics, and clinical trial design to create a more efficient and effective approach to drug development and early commercial viability. The work will focus on three key service areas: drug development strategy and analytics, clinical development, and asset valuation and due diligence.

Rob Kotchie, president of Real World Solutions at IQVIA, commented, "Working with Flagship Pioneering to foster the development of emerging biopharma companies that will advance the development of life-saving therapies fits squarely within IQVIA's mission to accelerate innovations for a healthier world and bring better treatments to patients faster."

David Khougazian, Executive Partner at Flagship Pioneering, added, "This collaboration brings enormous value to our platform companies by providing them the potential to greatly expand their reach and impact. By using IQVIA's robust data infrastructure and analytics capabilities alongside Flagship's pioneering bioplatforms, this collaboration is poised to positively impact the ability of our companies to accelerate their platform capabilities and drive value creation for life sciences."

About IQVIA
IQVIA (NYSE: IQV) is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. With approximately 88,000 employees in over 100 countries, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

About Flagship Pioneering
Flagship Pioneering invents and builds bioplatform companies to give each the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $60 billion in aggregate value. The current Flagship ecosystem comprises over 40 companies, including Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, Inari, Indigo Agriculture, Lila Sciences, Tessera Therapeutics, and Valo Health.

References:
[1] https://www.morningstar.com/news/pr-newswire/20250828ne60276/iqvia-and-flagship-pioneering-announce-strategic-collaboration-to-accelerate-the-development-of-breakthrough-life-sciences-companies
[2] https://www.ainvest.com/news/revolutionizing-biopharma-natera-ai-driven-precision-medicine-platform-catalyst-drug-development-investor-2508/